Targeting CENPN to inhibit breast cancer progression: insights into cell growth and aerobic glycolysis modulation

Breast cancer represents a significant health challenge for women globally. Although centromere protein N (CENPN) is reported to be upregulated in breast cancer, its detailed role remains unclear. This study used in silico analysis to investigate the expression profile and survival impact of CENPN in breast cancer. The CENPN level was evaluated using real-time quantitative polymerase chain reaction and western blot assays. The influence of CENPN on cell proliferation and aerobic glycolysis was investigated through cell counting kit-8, 5-ethynyl-2′-deoxyuridine incorporation assays, measurements of the extracellular acidification rate (ECAR), glucose uptake, lactate production, and additional western blot analyses. Moreover, in vivo studies on xenografted mice were conducted, utilizing immunohistochemistry and western blot techniques to evaluate the functions of CENPN. These findings revealed an upregulation of CENPN, correlating with decreased survival rates in breast cancer patients. Functionally, CENPN was shown to stimulate cell growth in both cell culture and animal models. Through gain- and loss-of-function experiments, CENPN was found to increase the ECAR, glucose uptake, lactate production, and the protein levels of glucose transporter 1 (GLUT1) and hexokinase 2 (HK2). Furthermore, CENPN was observed to increase the levels of phosphorylated protein kinase B (AKT) (p-AKT) relative to total AKT and hypoxia-inducible factor 1α (HIF-1α) in both cellular and animal models. The HIF-1α overexpression mitigated the suppressive effects of sh-CENPN on cell proliferation and aerobic glycolysis in breast cells. In conclusion, CENPN is upregulated and is related to a lower survival probability in breast cancer. It facilitates cell growth and aerobic glycolysis by upregulating AKT/HIF-1α signaling pathways. These insights provide novel perspectives for the diagnosis and treatment of breast cancer.

Breast cancer; CENPN; Growth; Aerobic glycolysis; PI3K/AKT; HIF-1α

[1] Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA: A Cancer Journal for Clinicians. 2023; 73: 17–48.

[2] Winters S, Martin C, Murphy D, Shokar NK. Breast cancer epidemiology, prevention, and screening. Progress in Molecular Biology and Translational Science. 2017; 136: 1–32.

[3] Miller KD, Nogueira L, Devasia T, Mariotto AB, Yabroff KR, Jemal A, et al. Cancer treatment and survivorship statistics, 2022. CA: A Cancer Journal for Clinicians. 2022; 72: 409–436.

[4] Krämer S, Rogmans C, Saylan D, Friedrich D, Kraft C, Rogmans G, et al. Treatment progress in triple negative breast cancer. European Journal of Gynaecological Oncology. 2022; 43: 341–352.

[5] Crosby D, Bhatia S, Brindle KM, Coussens LM, Dive C, Emberton M, et al. Early detection of cancer. Science. 2022; 375: eaay9040.

[6] Cairns RA, Harris IS, Mak TW. Regulation of cancer cell metabolism. Nature Reviews Cancer. 2011; 11: 85–95.

[7] Orang AV, Petersen J, McKinnon RA, Michael MZ. Micromanaging aerobic respiration and glycolysis in cancer cells. Molecular Metabolism. 2019; 23: 98–126.

[8] Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009; 324: 1029–1033.

[9] Cantor JR, Sabatini DM. Cancer cell metabolism: one hallmark, many faces. Cancer Discovery. 2012; 2: 881–898.

[10] Feng Y, Xiong Y, Qiao T, Li X, Jia L, Han Y. Lactate dehydrogenase a: a key player in carcinogenesis and potential target in cancer therapy. Cancer Medicine. 2018; 7: 6124–6136.

[11] Schug Z, Vande Voorde J, Gottlieb E. The nurture of tumors can drive their metabolic phenotype. Cell Metabolism. 2016; 23: 391–392.

[12] Lunt SY, Vander Heiden MG. Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annual Review of Cell and Developmental Biology. 2011; 27: 441–464.

[13] Park JH, Pyun WY, Park HW. Cancer metabolism: phenotype, signaling and therapeutic targets. Cells. 2020; 9: 2308.

[14] Wu Z, Wu J, Zhao Q, Fu S, Jin J. Emerging roles of aerobic glycolysis in breast cancer. Clinical and Translational Oncology. 2020; 22: 631–646.

[15] Su K, Tsang M, Emans N, Cheeseman IM. CRISPR/Cas9-based gene targeting using synthetic guide RNAs enables robust cell biological analyses. Molecular Biology of the Cell. 2018; 29: 2370–2377.

[16] Chittori S, Hong J, Saunders H, Feng H, Ghirlando R, Kelly AE, et al. Structural mechanisms of centromeric nucleosome recognition by the kinetochore protein CENP-N. Science. 2018; 359: 339–343.

[17] Zheng Y, You H, Duan J, Chen B, Wu C, Chen P, et al. Centromere protein N promotes lung adenocarcinoma progression by activating PI3K/AKT signaling pathway. Genes & Genomics. 2022; 44: 1039–1049.

[18] Xu S, Wei X. Knockdown of CENPN inhibits glucose metabolism and induces G1 arrest in esophageal cancer cells by regulating PI3K/AKT signaling pathway. Horm Metab Res. 2023; 55: 563–572.

[19] Qi CL, Huang ML, Zou Y, Yang R, Jiang Y, Sheng JF, et al. The IRF2/CENP-N/AKT signaling axis promotes proliferation, cell cycling and apoptosis resistance in nasopharyngeal carcinoma cells by increasing aerobic glycolysis. Journal of Experimental & Clinical Cancer Research. 2021; 40: 390.

[20] Andres SA, Bickett KE, Alatoum MA, Kalbfleisch TS, Brock GN, Wittliff JL. Interaction between smoking history and gene expression levels impacts survival of breast cancer patients. Breast Cancer Research and Treatment. 2015; 152: 545–556.

[21] Wang Y, Li Y, Liu B, Song A. Identifying breast cancer subtypes associated modules and biomarkers by integrated bioinformatics analysis. Bioscience Reports. 2021; 41: BSR20203200.

[22] Yang X, Gong J, Cai X, Yuan Y. Overexpression of HIC1 plays a protective effect on renal cell injury caused by lipopolysaccharide by inhibiting IL-6/STAT3 pathway. Signa Vitae. 2022; 18: 147–153.

[23] He Y, Li Q, Zhou W, Gu Y, Jiang Y. Coniferyl aldehyde alleviates LPS-induced WI-38 cell apoptosis and inflammation injury via JAK2-STAT1 pathway in acute pneumonia. Allergologia et Immunopathologia. 2021; 49: 72–77.

[24] Zhang Y, Wu T, Zhao B, Liu Z, Qian R, Zhang J, et al. E239K mutation abolishes the suppressive effects of lysine‐specific demethylase 1 on migration and invasion of MCF7 cells. Cancer Science. 2022; 113: 489–499.

[25] Chhabra R, Rao S, Kumar BM, Shetty AV, Hegde AM, Bhandary M. Characterization of stem cells from human exfoliated deciduous anterior teeth with varying levels of root resorption. Journal of Clinical Pediatric Dentistry. 2021; 45: 104–111.

[26] Lee EH, Lee JN, Park S, Chun SY, Yoon BH, Chung J-W, et al. Inhibition of TRPM7 suppresses migration and invasion of prostate cancer cells via inactivation of ERK1/2, Src and Akt pathway signaling. Journal of Men’s Health. 2022; 18: 1–10.

[27] Xie J, Zhou Y, Ge Y. The expression and prognostic value of minichromosome maintenance markers in human breast cancer: a comprehensive analysis. European Journal of Gynaecological Oncology. 2022; 43: 227–237.

[28] Huang Y, Liu Y, Lian S, Cai Z, Tang Y, Wei C. Clinical diagnostic and prognostic value of plasma Hsp90α in invasive breast cancer. European Journal of Gynaecological Oncology. 2022; 43: 58–63.

[29] An T, Guo L. Comprehensive analysis of STAT family members as prognostic markers in human breast cancer. European Journal of Gynaecological Oncology. 2022; 43: 55–70.

[30] Li X, Li Y, Du X, Wang X, Guan S, Cao Y, et al. HES1 promotes breast cancer stem cells by elevating Slug in triple-negative breast cancer. International Journal of Biological Sciences. 2021; 17: 247–258.

[31] Zhang L, Wang L, Yang H, Li C, Fang C. Identification of potential genes related to breast cancer brain metastasis in breast cancer patients. Bioscience Reports. 2021; 41: BSR20211615.

[32] Wang X, Lai M, Wang Y, Chai R, Li N, Ou L, et al. Upregulation of centromere proteins as potential biomarkers for esophageal squamous cell carcinoma diagnosis and prognosis. BioMed Research International. 2022; 2022: 3758731.

[33] Wang X, Zhang K, Fu C, Wu F, Zhang J, Han B, et al. High expression of centromere protein N as novel biomarkers for gastric adenocarcinoma. Cancer Reports. 2023; 6: e1798.

[34] Han J, Wang Y, Yang R, Xu Y, Li F, Jia Y. LncRNA FAM225a activates the cGAS-STING signaling pathway by combining FUS to promote CENP-N expression and regulates the progression of nasopharyngeal carcinoma. Pathology—Research and Practice. 2022; 236: 154005.

[35] Yang P, Pei X, Deng J, Li X. Comprehensive analysis of centromere protein family member genes in lung adenocarcinoma. Critical Reviews in Eukaryotic Gene Expression. 2022; 32: 57–72.

[36] Wu H, Zhou Y, Wu H, Xu L, Yan Y, Tong X, et al. CENPN acts as a novel biomarker that correlates with the malignant phenotypes of glioma cells. Front Genet. 2021; 12: 732376.

[37] Wang Q, Yu X, Zheng Z, Chen F, Yang N, Zhou Y. Centromere protein N may be a novel malignant prognostic biomarker for hepatocellular carcinoma. PeerJ. 2021; 9: e11342.

[38] Oka N, Kasamatsu A, Endo-Sakamoto Y, Eizuka K, Wagai S, Koide-Ishida N, et al. Centromere protein N participates in cellular proliferation of human oral cancer by cell-cycle enhancement. Journal of Cancer. 2019; 10: 3728–3734.

[39] Kim J. In silico analysis of differentially expressed genesets in metastatic breast cancer identifies potential prognostic biomarkers. World Journal of Surgical Oncology. 2021; 19: 188.

[40] Zhang Z, Zou Z, Dai H, Ye R, Di X, Li R, et al. Key genes involved in cell cycle arrest and DNA damage repair identified in anaplastic thyroid carcinoma using integrated bioinformatics analysis. Translational Cancer Research. 2020; 9: 4188–4203.

[41] Rahman MR, Islam T, Gov E, Turanli B, Gulfidan G, Shahjaman M, et al. Identification of prognostic biomarker signatures and candidate drugs in colorectal cancer: insights from systems biology analysis. Medicina. 2019; 55: 20.

[42] Yang Q, Jiang W, Hou P. Emerging role of PI3K/AKT in tumor-related epigenetic regulation. Seminars in Cancer Biology. 2019; 59: 112–124.

[43] Li J, Goh ELK, He J, Li Y, Fan Z, Yu Z, et al. Emerging intrinsic therapeutic targets for metastatic breast cancer. Biology. 2023; 12: 697.

[44] Pandey S, Mondal S, Kajal K, Kurmi BD, Verma SK, Patel P. Current progress in the targeted therapy of breast cancer: structure-activity correlation and docking studies (2015–2021). Archiv der Pharmazie. 2023; 356: e2200602.

[45] Malayil R, Chhichholiya Y, Vasudeva K, Singh HV, Singh T, Singh S, et al. Oncogenic metabolic reprogramming in breast cancer: focus on signaling pathways and mitochondrial genes. Medical Oncology. 2023; 40: 174.

[46] Zhou P, Zheng Z, Wan T, Wu J, Liao C, Sun X. Vitexin inhibits gastric cancer growth and metastasis through HMGB1-mediated inactivation of the PI3K/AKT/mTOR/HIF-1α signaling pathway. Journal of Gastric Cancer. 2021; 21: 439.

[47] Robey IF, Lien AD, Welsh SJ, Baggett BK, Gillies RJ. Hypoxia-inducible factor-1a and the glycolytic phenotype in tumors. Neoplasia. 2005; 7: 324–330.

[48] Yang H, Lin P, Vadivalagan C, Lin Y, Lin K, Hseu Y. Coenzyme Q0 defeats NLRP3-mediated inflammation, EMT/metastasis, and Warburg effects by inhibiting HIF-1α expression in human triple-negative breast cancer cells. Archives of Toxicology. 2023; 97: 1047–1068.

[49] Liu B, Qu X, Wang J, Xu L, Zhang L, Xu B, et al. LINC00365 functions as a tumor suppressor by inhibiting HIF-1α-mediated glucose metabolism reprogramming in breast cancer. Experimental Cell Research. 2023; 425: 113514.